Want to see SE:ORX full AI Analyst Report?
ORX Stock Chart & Stats
kr13.54
kr0.28(1.84%)
At close: 4:00 PM EDT
kr13.54
kr0.28(1.84%)
Day’s Range― - ―
52-Week Rangekr12.54 - kr43.40
Previous CloseN/A
Volume21.89K
Average Volume (3M)40.13K
Market Cap
kr447.00M
Enterprise Valuekr576.03
Total Cash (Recent Filing)kr276.90M
Total Debt (Recent Filing)kr9.90M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Oct 22, 2026EPS Estimate
-2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.81
Shares Outstanding35,127,056
10 Day Avg. Volume32,094
30 Day Avg. Volume40,132
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.03
Revenue Forecast (FY)kr26.00M
Bulls Say, Bears Say
Bulls Say
Long-lived IP And Pipeline OptionalityLong IP protection gives Orexo more time to develop, partner, and commercialize its pipeline while limiting direct competition. OX640, GLP-1 work, and the AmorphOX platform provide potential future growth avenues beyond the company’s current marketed products.
BARDA-backed Development And Partnering PotentialBARDA support reduces Orexo’s direct funding burden for OX390 and validates the program’s strategic relevance. Intensifying partnering efforts for OX640 and Izipry could further improve commercialization capacity and help share development costs over time.
Improved Leverage ProfileVery low debt relative to equity provides greater financial flexibility than Orexo had in periods of higher leverage. Although profitability remains weak, the improved solvency profile can help the company manage development priorities and pursue partnerships without the same debt burden.
Bears Say
Deep Losses And Revenue ContractionOrexo’s core economics remain fragile because revenue has contracted while gross profit and operating margins are sharply negative. Recurring losses indicate that the existing business is not covering its cost base, making sustainable earnings dependent on pipeline progress or a material commercial recovery.
High Cash Burn And Uncertain Cash-flow DurabilityThe quarterly cash outflow materially reduced available liquidity while revenues remained very low, increasing dependence on operating improvement, partnerships, or financing. Although TTM cash flow had improved, the continuing net losses and volatile history make that improvement difficult to treat as durable.
Unresolved DOJ InvestigationOngoing DOJ uncertainty creates a durable overhang on financial planning because the eventual settlement amount and timing are not established. It has also increased legal expenses and may constrain or delay attractive financing, limiting Orexo’s flexibility while it funds development.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr12.54 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr447.00M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 30 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -kr2.2 earnings per share for the quarter, missing the consensus estimate of -kr1.6 by -kr0.6.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -2.1.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr2.2 in its last earnings report, missing expectations of -kr1.6. Following the earnings report the stock price went down -16.279%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
ORX Company Deck
ORX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all SE:ORX earnings summariesTechnical Analysis
Swedish Orphan Biovitrum AB
―
Camurus AB
―
AlzeCure Pharma AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―